Lars Thore Burgdorf

USPTO Granted Patents = 24 (Patent Applications = 5)

CIPO Patents = 5

EPO Patents = 20 (Patent Applications = 16)

Average Co-Inventor Count = 5.5

ph-index = 4

Forward Citations = 71(Granted Patents)

Company Filing History:

Merck Patent Gesellschaft MIT Beschrankter Haftung

patents

1 out of 121

Merck Patent Gesellschaft

patents

Years Active: 2008-2025

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12371430 - 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives (2025-07-29),

2. 11939314 - Quinolin-2-one derivatives (2024-03-26),

3. 11186562 - Quinolin-2-one derivatives (2021-11-30),

4. 11174241 - Quinolin-2-one derivatives (2021-11-16),

5. 10669251 - Quinolin-2-one derivatives (2020-06-02),

6. 10570149 - Tricyclic heterocylic derivatives (2020-02-25),

7. 9725462 - Pyridopyrimidine derivatives as protein kinase inhibitors (2017-08-08),

8. 9120804 - 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors (2015-09-01),

9. 9023851 - Triazolopyrazine derivatives (2015-05-05),

10. 9006440 - Furopyridine derivatives (2015-04-14),

11. 8546390 - 6-(pyrrolopyridinyl) pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and AIDS (2013-10-01),

12. 8431602 - Beta-amino acid derivatives for treatment of diabetes (2013-04-30),

13. 8420642 - Pyridine derivatives useful as glucokinase activators (2013-04-16),

14. 8383838 - 5-oxo-2,3,4,5-tetrahydro-benzo[b]oxepine-4-carboxylic acid amides and 2,3-dihydro-benzo[b]oxepine-4-carboxylic acid amides for treatment and prevention of diabetes typ 1 and 2 (2013-02-26),

15. 8236824 - N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators (2012-08-07),

Title: The Innovations of Lars Thore Burgdorf

Introduction

Lars Thore Burgdorf, based in Frankfurt-am-Main, Germany, is an esteemed inventor renowned for his contributions to the field of pharmaceuticals. With an impressive portfolio of 23 patents, Burgdorf has made significant advancements in the development of innovative therapies aimed at treating various medical conditions, including cancer.

Latest Patents

Among his latest innovations are the Quinolin-2-one derivatives, which are compounds described by the formula I. These compounds serve as inhibitors of c-Kit kinase, making them valuable in therapeutic applications for cancer treatment. The ingenuity behind these derivatives showcases Burgdorf’s commitment to finding novel solutions to complex health issues.

Career Highlights

Burgdorf has had a notable career, holding positions at prominent companies such as Merck Patent GmbH and Merck Patent Gesellschaft mit beschränkter Haftung. His tenure at these organizations has allowed him to refine his inventive skills and contribute to groundbreaking research and development initiatives.

Collaborations

Throughout his career, Burgdorf has collaborated with esteemed colleagues, including Norbert Beier and Dieter Dorsch. These partnerships have not only enriched his work but also fostered an environment of shared knowledge and expertise, contributing to the overall success of their projects.

Conclusion

Lars Thore Burgdorf stands out as a notable figure in the world of pharmaceuticals, with his patents reflecting a dedication to innovation in medical science. His work continues to inspire future advancements that may significantly impact cancer treatment and beyond.

This text is generated by artificial intelligence and may not be accurate.